Barrier lymphocytes in spondyloarthritis.
Barrier lymphocytes in spondyloarthritis.
复制标题
DOI：
10.1097/bor.0000000000000716
复制
发表时间：
2020-07
影响因子：
5.1
通讯作者：
Kuhn KA
中科院分区：
文献类型：
--
作者：
Berlinberg A;Kuhn KA
脊柱性关节炎(SpA)与肠道和皮肤等屏障组织炎症之间的临床重叠表明屏障组织免疫在SpA的发展中起着作用。在这里，我们综述了最近的进展，了解淋巴细胞种群和功能在肠道和皮肤中涉及的SpA的病理生理。许多独特的淋巴细胞在SpA患者的肠道和皮肤中被发现，包括γδT细胞、粘膜相关不变T细胞、先天淋巴样细胞和T驻留记忆细胞。这些细胞对其屏障表面的微生物信号做出反应，导致细胞激活和产生白介素17，这被认为是它们促进SpA发病的机制。了解独特的淋巴细胞群体如何在SpA的发展过程中扩张和产生IL-17有助于深入了解这种疾病的病理生理学以及潜在的未来治疗途径。
The clinical overlap between spondyloarthritis (SpA) and inflammation of barrier tissues such as the intestine and skin indicates a role of barrier tissue immunity in the development of SpA. Herein, we review the recent advances in understanding lymphocyte populations and functions within the intestine and skin implicated in the pathophysiology of SpA. A number of unique lymphocyte populations have been identified to be expanded within the gut and skin of patients with SpA, including γδ T cells, mucosa-associated invariant T (MAIT) cells, innate lymphoid cells (ILCs) and T resident memory (TRM) cells. These cells respond to microbial cues at their barrier surface causing cellular activation and generation of interleukin (IL)-17, which is hypothesized to be the mechanism by which they contribute to SpA pathogenesis. Understanding how unique lymphocyte populations expand and produce IL-17 in the development of SpA provides insights into the pathophysiology of this disease as well as potential future therapeutic avenues.